Evidence map›Paper›PMID 31890725›Full record

ArticleOpen forum infectious diseases2019

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Sarah C J Jorgensen, Trang D Trinh, Evan J Zasowski, Abdalhamid M Lagnf, Sahil Bhatia, Sarah M Melvin, Molly E Steed, Samuel P Simon, Sandra J Estrada, Taylor Morrisette and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ceftazidime-Avibactam in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Difficult-to-TreatAntibiotics (Basel, Switzerland) · 2025
    Review
  16. Observational
  17. Article
  18. Clinical experience with ceftazidime/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  19. Article
  20. Clinical outcomes and emergence of resistance ofAntimicrobial agents and chemotherapy · 2024
    Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Sarah C J JorgensenAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Trang D TrinhAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Evan J ZasowskiAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Abdalhamid M LagnfAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sahil BhatiaAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sarah M MelvinAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Molly E SteedDepartment of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City, Kansas, USA.
Samuel P SimonBrooklyn Hospital, Brooklyn, New York, USA.
Sandra J EstradaDepartment of Pharmacy, Lee Health, Fort Myers, Florida, USA.
Taylor MorrisetteAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Kimberly C ClaeysDepartment of Pharmacy Practice, School of Pharmacy, University of Maryland, Baltimore, MD, USA.
Joshua R RosenbergBrooklyn Hospital, Brooklyn, New York, USA.
Susan L DavisAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Eugene Applebaum College of Pharmacy and Health Sciences · USBrooklyn Hospital Center · USWayne State University · USLee Memorial Health System · USUniversity of Kansas · USUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe conducted this study to describe the clinical characteristics, microbiology, and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug-resistant Gram-negative (MDR-GN) infections.

methodsThis is a multicenter, retrospective cohort study conducted at 6 medical centers in the United States between 2015 and 2019. Adult patients who received CZA (≥72 hours) were eligible. The primary outcome was clinical failure defined as a composite of 30-day all-cause mortality, 30-day microbiological failure, and/or failure to resolve or improve signs or symptoms of infection on CZA.

resultsIn total, data from 203 patients were evaluated. Carbapenem-resistant Enterobacteriaceae (CRE) and

conclusionsCeftazidime-avibactam is being used to treat a range of MDR-GN infections including

Indexed as

carbapenem-resistant Enterobacteriaceaeceftazidime-avibactammultidrug-resistant Pseudomonas aeruginosa

Identifiers

PMID31890725
PMCPMC6934163
OpenAlexW2991949326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.